Private equity firm KKR teamed up with OMX Ventures to lead the seed investment in Replay, a company developing a suite of technologies that could overcome capacity limitations of adeno-associated viruses used for genetic medicines delivery. Duchenne muscular dystrophy is among the disease targets of the new startup.
The DNA currently used in genetic medicines research is synthesized by chemical methods. Ansa Biotechnologies employs faster and less expensive enzymes-based technology, and the startup has raised capital to scale up operations as it prepares to launch its service.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The Lilly Institute for Genetic Medicine is a new facility in Boston that will focus on the R&D of RNA and DNA-based therapies. Eli Lilly is investing about $700 million to establish the site, which will also include lab and office space for biotech startups.
The Illinois-based health system is teaming up with the analytics company to launch a genomics program, which will focus on predicting the risk of illness and outcomes among patients. It will also provide free genetic testing to low-income patients in an effort to increase access to genomic care.
Helix, based near San Francisco, touts its API-based business model as a way to stand out among the plethora of personal genomics companies.
Collaboration will leverage genetic testing company's data resources and pharma companies drug-development expertise.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The Danville, Pennsylvania-based system plans to work with rabbittransit to help patients get to their appointments on time. Additionally, researchers from Geisinger and Regeneron Genetics Center recently found a gene variant that's associated with a reduction in the risk for chronic liver disease.
Helix and Illumina Accelerator have paired up and will give entrepreneurs the chance to develop innovative, DNA-driven products geared toward consumers.
Willing patients who agree to participate in research, and give samples are key to progressing precision medicine and data shows there isn't any dearth of these medical philanthropists.
It's possible that the air we are breathing could be identifying, much like a fingerprint or DNA from our hair.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The ripple-effect of last week’s 23andMe news is just the beginning. A new study and an important genomics conference will only further highlight the opportunities coming in personalized medicine. New analysis from Frost & Sullivan, Future of Personalized Genomics, shows that genetic tests provided by companies straight to consumers via the e-commerce platform are more affordable […]
Storing data with things like USP sticks and discs just won’t cut it when it comes to the long-term historical picture, which is why researchers are turning to DNA for major data storage that could last the ages. Not only can 1 gram of DNA hold 455 exabytes of data (enough to hold everything from […]
In the first genetic profile of a metropolitan transit system, Weill Cornell Medical College researcher Christopher Mason and his team spent 18 months swabbing 466 subway stations in New York City. The findings were published in the journal Cell Systems. He says in many ways the results are “a mirror of the people themselves who ride […]
OK. This is pretty unsettling, but a recent survey put together by the Oklahoma State University Department of Agricultural Economics found that 80.44 percent of respondents were all for a government policy mandating labels on foods containing DNA. Not genetically modified foods (GMOs) or things we should practically be concerned about monitoring, but DNA. Genetic […]
Well, this is tragic. James Watson – yes, the Watson & Crick Watson – is auctioning off his Nobel Prize because he’s short of cash. Ever since a public outing of some IQ-related racist comments, the laureate told the Financial Times that he’s now considered an “unperson.” Watson, who earned the accolade in 1962 for discovering the structure of DNA, will auction off […]